Finance

Lists
Q2 2027 earnings • released • Revenue beat +4.30%
See results
4568:TYO
Daiichi Sankyo Co Ltd
¥2,892.50
+5.03%
(+138.50) 1D
Nov 2, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4568...
Open
¥2,828
High
¥2,892
Low
¥2,800
Mkt. cap
5.39T
Avg. vol.
7.36M
Volume
13.66M
Dividend
3.08%
Quarterly dividend
¥22
P/E ratio
21.91
52-wk high
¥3,913
52-wk low
¥2,390
EPS
¥132
Shares outstanding
647.77M
No. of employees
20K
Open
¥2,828
High
¥2,892
Low
¥2,800
Mkt. cap
5.39T
Avg. vol.
7.36M
Volume
13.66M
Dividend
3.08%
Quarterly dividend
¥22
P/E ratio
21.91
52-wk high
¥3,913
52-wk low
¥2,390
EPS
¥132
Shares outstanding
647.77M
No. of employees
20K
News stories
From web sources and news partners
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees20.2K
FoundedSep 28, 2005
HeadquartersChuo City, Tokyo, Japan
Sector-
Websitedaiichisankyo.co.jp
Last report
Oct 30, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
592.49B / 568.07B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
558.11B
589.59B
574.74B
592.49B
Cost of goods sold
118.28B
302.44B
124.29B
121.50B
Cost of revenue
118.28B
302.44B
124.29B
121.50B
Research and development expenses
122.11B
126.23B
115.46B
124.60B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
228.23B
154.06B
249.96B
237.75B
Operating expense
350.29B
279.38B
365.35B
362.29B
Total operating expenses
468.57B
581.82B
489.64B
483.79B
Operating income
89.54B
7.77B
85.10B
108.70B
Other non operating income
-
6.22B
-2.00M
-
EBT including unusual items
106.73B
22.44B
91.34B
101.51B
EBT excluding unusual items
106.73B
7.84B
91.34B
101.51B
Income tax expense
20.10B
-39.84B
22.70B
17.10B
Effective tax rate
18.83%
-177.52%
24.86%
16.84%
Other operating expenses
-49.00M
-908.00M
-69.00M
-60.00M
Net income
86.63B
62.28B
68.64B
82.90B
Net profit margin
15.52%
10.56%
11.94%
13.99%
Earnings per share
-
-
-
-
Interest and investment income
19.08B
377.00M
9.74B
6.41B
Interest expense
-2.16B
-18.91B
-3.23B
-14.13B
Net interest expenses
16.91B
-18.53B
6.51B
-7.72B
Depreciation and amortization charges
-
-
-
-
EBITDA
109.18B
28.89B
106.58B
130.56B
Gain or loss from assets sale
573.00M
8.50B
180.00M
3.24B
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps